GLP-1


Also found in: Acronyms, Wikipedia.

GLP-1

Abbreviation for glucagonlike peptide.

GLP-1

abbreviation for glucagon-like peptide 1.

GLP-1

Abbreviation for glucagonlike peptide.

GLP-1

A glucagon-like neuropeptide claimed to be an obesity mediator. Starved rats given the drug behave as if satiated and this state is reversed if given a GLP-1 antagonist.
References in periodicals archive ?
It is almost certain that humans have this protein, GLP-1, glucagon-like factor-1, in their brains, the researchers said, since it has been found in identical form in every vertebrate species looked at thus far, from fish to mammals.
This class is most often prescribed as a second-line approach, while GLP-1 receptor agonists are considered for third-line or later.
GLP-1 is a naturally-occurring peptide hormone that is released within minutes after eating a meal.
The European Medicines Agency and the US Food and Drug Administration have launched a review of GLP-1 drugs and have said that more research needs to be done before regulators can declare them safe.
GLP-1 is a peptide naturally released in the gut after food intake
According to interviewed Brazilian payers, insulin analogue manufacturers do not currently provide discounts through patient assistance programs, and although some GLP-1 analogue manufacturers offer discounts of up to 50 percent on their drugs through such programs, the substantial outstanding cost means treatment remains inaccessible to most public patients.
No GLP-1 receptor antagonists are licensed for treating CHI or other related conditions, however experimental and clinical studies with an intravenous peptide antagonist strongly indicate their prospective effectiveness.
Appetite was significantly reduced during the combination treatment compared to the glucagon, GLP-1 alone or saline infusions.
But blocking the effect of GLP-1 in the brain made mice perform more poorly on learning and memory tasks, while boosting it with the drug seemed to have no effect on behaviour.
The GLP-1 analogue is part of a new family of GLP-1 analogues discovered by
The 1-minute half-life of native GLP-1 means that for diabetic patients, it would need to be administered via an impractical continuous pump infusion.